CRISPR Cas9 Market Research Report 2024: Positioned for Exponential Growth with Advancements in Gene Therapy - Outlook to 2029
In a recent industry analysis, the medical community has witnessed significant progress in the area of CRISPR/Cas9 therapies. Experts predict that with several therapies demonstrating efficacy and safety, the market is positioned to welcome a new wave of regulatory approvals in the next half-decade.
Market Expansion and Clinical Trials
Stemming from demanding medical needs and the growing number of genetic disorders worldwide, CRISPR/Cas9 therapies are experiencing a rapid ascension in clinical trials and applications. This not only includes the management of cancers and genetic diseases but is expanding to address cardiovascular, neurodegenerative, and CNS diseases as well.
Innovations and Therapeutic Applications
CRISPR/Cas9's revolutionary gene-editing capabilities are forecasted to transform numerous medical and biotechnological fields, as ongoing clinical trials progress towards late-stage development. For example, Intellia Therapeutics' latest phase III study on NTLA-2001 promises to be a landmark in gene therapy for transthyretin amyloidosis with cardiomyopathy.
Market Projections and Financial Implications
The market for CRISPR/Cas9 therapies is estimated to grow significantly, potentially becoming a multi-billion-dollar industry. The US currently leads in research and development activities, but other regions like the EU are rapidly progressing. The first commercial CRISPR/Cas9 therapy, Casgevy, has been introduced at a considerable cost, reflective of its innovative value and therapeutic potential.
Conclusion and Future Prospects
CRISPR/Cas9 therapies represent a bold step forward for medical science, with the backing of crucial industry players and increasing technological advancements. This burgeoning field promises new treatments for patients across a spectrum of conditions, aligning with investments, collaborations, and strategic market movements within the pharmaceutical and biotechnology sectors. The next decade is set to be transformative for CRISPR/Cas9 therapy and its applications in the fight against disease.
Keep abreast of the market's growth and upcoming clinical trials advances for a brighter future in health treatments and therapies. This significant leap in genetic editing isn't just a milestone for the industry—it's a harbinger of hope for patients worldwide.
A selection of companies mentioned in this report includes, but is not limited to:
4D Molecular Therapeutics
Arbor Biotechnologies
ASC Therapeutics
C4U Corporation
Casebia Therapeutics
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
Nkarta Therapeutics
Vertex Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/lfz4ss
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: BIOTECHNOLOGY GENETICS HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2025.
PUB: 03/28/2025 09:09 AM/DISC: 03/28/2025 09:09 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Which Gene Therapy Technology Wins? New Data from Spherix Global Insights Reveals Emerging Hematologist Preferences in Beta Thalassemia Care
New research from Spherix Global Insights reveal Vertex/CRISPR Therapeutics' Casgevy holding a competitive edge over bluebird bio's Zynteglo as preferred beta thalassemia gene therapies. EXTON, PA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is emerging within the hematology community: whether the future belongs to gene editing or gene addition. Recent physician survey data from Market DynamixTM: Transfusion-Dependent Thalassemia reveal a clear shift in preference toward the CRISPR/Cas9-based therapy Casgevy with half of hematologists now favoring it, compared to just one-fifth for Zynteglo, a lentiviral vector-based therapy. The remaining respondents express no strong preference, citing similar efficacy and safety profiles in clinical trials. Casgevy (exagamglogene autotemcel, Vertex/CRISPR Therapeutics) uses CRISPR/Cas9 gene editing to disable the BCL11A enhancer, reactivating the body's natural production of fetal hemoglobin (HbF) – an oxygen-carrying molecule that can compensate for defective β-globin. 'Potential for more efficient editing and promising efficacy data,' one physician noted, adding that Casgevy's 'novel CRISPR platform' and accumulating real-world experience were compelling advantages. Zynteglo (betibeglogene autotemcel, bluebird bio) takes a different approach: inserting a functional HBB (β-globin) gene into a patient's hematopoietic stem cells via a lentiviral vector, restoring normal hemoglobin production. Physicians highlight its 'higher rate of transfusion independence (90–95% in long-term studies),' 'well-established safety profile,' and 'durable results' as support for their preference. While some clinicians see Casgevy as a leap forward in precision and efficiency, others value Zynteglo's longer track record and direct β-globin restoration. For many, the choice remains personalized, depending on patient genotype, treatment center expertise, insurance coverage, and patient or family comfort with each technology. Despite the promise of both therapies, physicians in suburban and rural areas report that demand for gene therapy exceeds available capacity. In addition, hematologists in the south and west are more likely to cite physical distance to certified gene therapy centers as a barrier. Even when centers are accessible, high upfront costs, lengthy insurance approvals, and constrained treatment slots can delay care. TDT is a severe inherited blood disorder requiring lifelong blood transfusions and iron chelation therapy. Gene therapy offers the potential for transfusion independence, but equitable access remains a critical challenge. Spherix will continue to monitor the hemoglobinopathy market, including thalassemia, through annual Market DynamixTM and Patient Chart DynamixTM services. Market Dynamix™ is an independent, data-driven service focused on understanding the evolving dynamics of specialty markets poised for disruption. Leveraging quantitative and qualitative research, the service evaluates current treatment approaches, unmet needs, and likely impact of pipeline agents over a three-to-five-year horizon. Patient Chart Dynamix™ is an independent service that includes robust patient chart audits and integrated specialist surveys fielded biannually. This research provides an in-depth, real-world view of treatment practices by combining verified patient data with attitudinal insights from physicians. The series highlights clinical decision-making, treatment sequencing, and outcomes for targeted patient populations across key therapeutic areas. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: Spherix Global Insights Contacts Sarah Hendry, Hematology Franchise Head NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Sarah Hendry, Hematology Franchise Head Spherix Global Insights 4848794284
Yahoo
a day ago
- Yahoo
Mexico Microcarrier Market Trends and Company Analysis Report 2025-2033 Featuring BD, Thermo Fisher Scientific, Merck, Eppendorf, Danaher, Sartorius, Bio Rad, Corning, Lonza Group, Getinge
The Mexico Microcarrier Market is poised for significant growth, projected to reach US$ 77.65 million by 2033 from US$ 39.96 million in 2024, achieving a CAGR of 7.66% from 2025 to 2033. Key drivers include increased investment in regenerative medicine and cell therapy, rising demand for cell-based vaccines and biologics, and technological advancements in cell culture efficiency. Mexico's biopharmaceutical sector expansion, supported by enhanced bioprocessing infrastructure and strategic public-private partnerships, further bolsters this growth. Emerging challenges include high setup costs and complex regulatory requirements, offering opportunities for innovation and collaboration. Mexican Microcarrier Market Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Mexico Microcarrier Market to Reach US$ 77.65 Million by 2033 - 7.66% CAGR Growth Driven by Biopharma Demand" report has been added to Mexico Microcarrier Market is expected to reach US$ 77.65 million by 2033 from US$ 39.96 million in 2024, with a CAGR of 7.66% from 2025 to 2033. Growing investment in regenerative medicine and cell therapy, growing demand for cell-based vaccines and biologics, technological advancements in culture efficiency, and expansion of biopharmaceutical research and development in Mexico. Mexico's growing biopharmaceutical and biotechnology industries depend heavily on the microcarrier industry. The large-scale manufacturing of biologics, vaccines, and cell treatments depends on microcarriers, which are tiny, spherical particles that promote the proliferation of adherent cells in bioreactors. As Mexico looks to improve its local manufacturing capabilities in response to growing healthcare demands and the need for medical product self-sufficiency, these applications become more and more market is expanding due to a number of causes. Research and development expenditures, along with the nation's strategic efforts to strengthen its biomanufacturing infrastructure, are essential. The need for effective cell culture systems is further fueled by the aging population and the rising incidence of chronic diseases, which increase demand for cutting-edge treatment solutions. Additionally, Mexico has easier access to cutting-edge biotechnologies, such as microcarrier-based cell culture systems, thanks to its involvement in international health programs and collaborations with foreign the encouraging growth trajectory, the Mexican microcarrier market still confronts obstacles including the requirement for specialized technological know-how and the development of strong regulatory frameworks to guarantee the quality and safety of the products. Nonetheless, these difficulties offer chances for creativity and cooperation. These problems can be resolved by creating training initiatives, establishing regulatory guidelines, and encouraging public-private partnerships. This will create an atmosphere that is favorable for the expansion of the microcarrier market and the larger biopharmaceutical sector in Factors Driving the Mexico Microcarrier Market Growth Increasing Demand for Cell Therapy and BiopharmaceuticalsMicrocarrier systems are in high demand due to Mexico's growing biopharmaceutical industry, which includes the manufacture of vaccines, biologics, and cell treatments. Businesses are depending more and more on microcarriers to sustain high density adherent cell cultures in bioreactors as local R&D becomes more intense and manufacturing capacity need is particularly noticeable in the creation of therapeutic proteins, monoclonal antibodies, and items related to regenerative medicine. Scalable and effective cell culture is made possible by microcarriers, which is necessary for the commercial production of biologics and sophisticated cell culture systems are now a vital enabling technology for Mexico's biomanufacturing efforts as the nation develops its capacities in these fields and aligns with international health Development and Manufacturing ExpansionMexico's bioprocessing infrastructure is being quickly strengthened through government sponsored initiatives and strategic public-private partnerships. The adoption of effective cell culture technologies is being fueled by investments in upstream bioprocessing facilities, automation, single use systems, and digital technology is also supported by the growth of industry academia partnership and regulatory modernization (e.g., COFEPRIS's digital transformation). These advancements promote easier technology transfer from research to production and improve the technical preparedness required for microcarrier is therefore better able to scale complex bioprocesses, which increases the accessibility of microcarriers for biotechnology companies, contract manufacturers, and academic institutions seeking to increase their capacity for and Technological Progress in MicrocarriersPerformance and scalability have been greatly enhanced by innovations in microcarrier design, such as surface functionalized beads, biodegradable materials, and compatibility with single use bioreactors. Manufacturers who prioritize quality and cost effectiveness are placing a greater value on enhanced features like increased yield, better cell adhesion, and lower contamination developments, when combined with automation, intelligent sensor integration, and digital process control, reduce human error and streamline production. Modern microcarrier formats are becoming feasible choices for biomanufacturers and researchers nation wide due to Mexico's rising alignment with international industry trends and the country's expanding adoption of state of the art bioprocessing in the Mexico Microcarrier Market Expensive Startup and Ongoing CostsMicrocarrier based cell culture system deployment requires a large financial outlay, especially for equipment such as bioreactors, single use systems, and associated infrastructure. Traditional planar culture techniques are still less expensive at lower scales because they require less like microcarrier beads make up a significant portion of the continuous expenses for microcarrier setups, which frequently require tens or even hundreds of thousands of dollars in capital expenditure. GMP grade, high quality microcarriers can account for 20-25% of total consumable financial barriers, in addition to media supplies and labor training, make the technology hard to adopt in Mexico, where a large number of biotech companies and academic institutions have tight budgets. Despite the long term productivity and efficiency benefits of microcarriers, this hinders scale of Regulations and Documentation NeedsUnder the General Health Law, COFEPRIS is in charge of regulating microcarrier based cell culture in Mexico, particularly when it is meant for clinical or therapeutic applications. In accordance with ICH guidelines, businesses are required to compile comprehensive Common Technical Document (CTD) dossiers that include clinical, non clinical, and quality is necessary to adhere to Official Mexican Standards (such as NOM?257?SSA1?2014, NOM?059?SSA1?2015), especially those that deal with GMP, bio comparability, and safety assessment. Microcarrier systems need to be thoroughly validated, which includes testing for batch uniformity, sterility, and cell material obstacles to commercialization include the burden of complicated documentation and testing, changing regulations, and unclear advanced therapeutic standards. Market access may be delayed, more expensive, and unclear for entities without local regulatory partnerships or past dossier experience. Company Analysis: Overview, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis Thermo Fisher Scientific Merck KGaA Eppendorf AG Danaher Corporation Sartorius AG Bio Rad Laboratories, Inc. Corning Inc. Lonza Group Getinge Becton, Dickinson and Company Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $39.96 Million Forecasted Market Value (USD) by 2033 $77.65 Million Compound Annual Growth Rate 7.6% Regions Covered Mexico Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Mexico Microcarrier Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product Type6.2 By Application6.3 By End User6.4 By Region7. Product Type7.1 Consumables7.1.1 Microcarrier Beads7.1.2 Media & Reagents7.2 Equipment8. Application8.1 Cell Therapy8.1.1 Market Analysis8.1.2 Market Size & Forecast8.2 Vaccine Manufacturing8.3 Others9. End User9.1 Pharmaceutical & Biotechnology Companies9.2 Contract Research Organizations & Contract Manufacturing Organizations9.3 Academic & Research Institutes10. Region10.1 Northern Mexico10.2 Central Mexico10.3 Southern Mexico10.4 Others11. Value Chain Analysis12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Competition12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threats14. Pricing Benchmark Analysis14.1 Thermo Fisher Scientific14.2 Merck KGaA14.3 Eppendorf AG14.4 Danaher Corporation14.5 Sartorius AG14.6 Bio-Rad Laboratories, Inc.14.7 Corning Inc.14.8 Lonza Group14.9 Getinge14.10 Becton, Dickinson and Company15. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Mexican Microcarrier Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Gizmodo
6 days ago
- Gizmodo
Diabetic Man With Gene-Edited Cells Produces His Own Insulin—No Transplant Drugs Required
A new case study offers a tantalizing glimpse into the potential future of transplantation medicine. A man with type 1 diabetes is now able to make his own insulin thanks to a transplant of gene-edited pancreatic cells—a transplant that hasn't required the typical drugs used to avoid rejection. Scientists in Sweden and the U.S. conducted the research, published this week in the New England Journal of Medicine. The 42-year-old man with long-standing diabetes was given donated islet cells that were genetically modified via CRISPR to prevent immune rejection. Roughly four months after the procedure, his fully gene-edited cells have continued to produce insulin without provoking an immune response. 'Our study, although preliminary, suggests that immune evasion is an alternative concept for the circumvention of allorejection,' the authors wrote in the paper. A New Diabetes Treatment Is on the Horizon—But It Involves Poop People with type 1 diabetes have immune systems that destroy the pancreatic cells responsible for making insulin. The condition can be managed with regular doses of synthetic insulin, but people's health still tends to worsen over time. Recently, scientists have been studying whether donated islet cell transplants can provide a self-sustained replacement supply of insulin for type 1 diabetics—an effective cure, in other words, provided the cells can survive long-term. Early clinical trials of the technology have looked promising so far, but these transplants still require lifelong immunosuppressive therapy to ensure the host's body doesn't go after the donated cells. Effective as these drugs are, they have their well-known drawbacks, such as weakening people's immunity to actual threats like infections. The study researchers have been experimenting with a unique approach to sidestep the need for these drugs. They first tested it on mice and monkeys, with this new case being the first test in humans. They created three specific edits in the donated cells, all intended to quiet the most likely responses from the immune system. Two of the edits deplete the cells' supply of HLA class I and II antigens, proteins that tell our T cells whether another cell is foreign or not. A third edit causes the donated cells to make more of another protein called CD47 that inhibits the activity of other immune cells that would normally target them. The researchers injected the modified cells into the man's forearm. The edits weren't completely successful in some of the cells, and the man's immune system quickly killed off these cells. But as hoped, his body left the fully edited cells alone, even without immunosuppressants. The surviving cells produced insulin as normal, and the man appeared to be doing well 12 weeks later. He did experience several adverse events, but none were serious or linked to the transplanted cells themselves (he had mildly inflamed veins where a catheter was placed, for instance). This study is only a proof of concept, geared more at showing the procedure can be done safely than at proving it actually works. The man was given a relatively low dose of the donated cells, likely too low for his body to produce enough insulin on its own to no longer need treatment. Follow-up is also needed to know whether these cells can survive long-term. In Medical First, Woman's Type 1 Diabetes Seemingly Cured by Stem Cells But there's much to be encouraged about. And it's the latest sign that scientists are truly on the verge of making type 1 diabetes curable. Other research teams have shown early success in using similar transplants to cure the condition, including some that have also avoided needing immunosuppressant therapy.
